New stock news | Yifang Biotechnology (688382.SH) submits application to Hong Kong Stock Exchange

According to the disclosure by the Hong Kong Stock Exchange on January 1st, Yifang Biotechnology (Shanghai) Co., Ltd. (referred to as Yifang Biotech) has submitted an application for listing on the Main Board of the Hong Kong Stock Exchange, with CITIC Securities as its exclusive sponsor. The prospectus shows that Yifang Biotech (688382.SH) is a research-driven biopharmaceutical company based in China with a global presence, focusing on significant disease areas such as tumors, autoimmune diseases, and metabolic diseases that have a large unmet need. As of December 24, 2025, the company has established a comprehensive and differentiated product pipeline, including two commercial products (BPI-D0316 and D 1553), two core products in clinical development (D-2570 and D-0502), a clinical-stage candidate product (D-0120), and three preclinical candidate products (YF087, YF550, and YF057).